Portal de Periódicos da CAPES

Does Stent Placement for Advanced Colon Cancer Increase the Risk of Perforation During Bevacizumab-Based Therapy?

2009; Elsevier BV; Volume: 7; Issue: 11 Linguagem: Inglês

10.1016/j.cgh.2009.07.015

1542-7714

Vincenzo Cennamo, Lorenzo Fuccio, V. Mutri, Maria Eugenia Minardi, Leonardo Henry Eusebi, Liza Ceroni, Liboria Laterza, Luca Ansaloni, Antonio Daniele Pinna, Nunzio Salfi, Andrea Martoni, Franco Bazzoli,

Gastric Cancer Management and Outcomes

Data on the safety of bevacizumab-based therapies for patients carrying a self-expandable metallic stent (SEMS) for occlusive colon cancer are lacking. We report 2 cases of colon perforation observed in our case series of patients with SEMS for occlusive colon cancer.Patients with occlusive symptoms caused by colon cancer received a colonic stent under endoscopic and radiologic guidance.Over a 10-month period, 28 patients with occlusive colon cancer were treated with stent placement. The stent was placed as a bridge to surgery in 12 patients who were treated surgically within 4 to 78 days after the endoscopic procedures, without any stent-related complications. Seven patients did not receive any other antitumor treatment as a result of concomitant comorbidities. Nine patients with both primary tumor and metastatic lesions were treated with medical therapy. Over a median follow-up period of 131 days colonic perforation occurred in the 2 patients treated with a combination of capecitabine and oxaliplatin plus bevacizumab.Further studies are needed to clarify whether SEMS placement increases the risk of perforation caused by bevacizumab-based therapies.